Research ArticleThe State of the Art
Treatment Landscape of Prostate Cancer in the Era of PSMA Radiopharmaceutical Therapy
Fabio Turco, Silke Gillessen, Ken Herrmann, Gaetano Paone and Aurelius Omlin
Journal of Nuclear Medicine May 2025, 66 (5) 665-672; DOI: https://doi.org/10.2967/jnumed.124.267730
Fabio Turco
1Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland;
Silke Gillessen
1Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland;
2Faculty of Biosciences, Università della Svizzera Italiana, Lugano, Switzerland;
Ken Herrmann
3Department of Nuclear Medicine, University of Duisburg-Essen, Essen, Germany; German Cancer Consortium, University Hospital Essen, Essen, Germany;
Gaetano Paone
2Faculty of Biosciences, Università della Svizzera Italiana, Lugano, Switzerland;
4Clinic of Nuclear Medicine and Molecular Imaging, Imaging Institute of Southern Switzerland, EOC, Bellinzona, Switzerland; and
Aurelius Omlin
5Onkozentrum Zurich, University of Zurich and Tumorzentrum Hirslanden Zurich, Zurich, Switzerland

Data supplements
Supplemental Data
Files in this Data Supplement:
In this issue
Journal of Nuclear Medicine
Vol. 66, Issue 5
May 1, 2025
Treatment Landscape of Prostate Cancer in the Era of PSMA Radiopharmaceutical Therapy
Fabio Turco, Silke Gillessen, Ken Herrmann, Gaetano Paone, Aurelius Omlin
Journal of Nuclear Medicine May 2025, 66 (5) 665-672; DOI: 10.2967/jnumed.124.267730
Jump to section
- Article
- Abstract
- HIGH-RISK LOCALIZED DISEASE
- HIGH-RISK BIOCHEMICAL RECURRENCE
- MHSPC SETTING
- GENERAL CRPC
- NMCRPC
- POSSIBLE SEQUENCE THERAPIES IN MCRPC
- TREATMENT OPTIONS AFTER ADT ALONE OR ADT PLUS DOCETAXEL FOR MHSPC
- TREATMENT OPTIONS AFTER ADT PLUS ARPI FOR MHSPC
- TREATMENT OPTIONS AFTER ADT PLUS ARPI PLUS DOCETAXEL FOR MHSPC
- GENERAL CONSIDERATIONS
- CONCLUSION
- DISCLOSURE
- Footnotes
- REFERENCES
- Figures & Data
- Supplemental
- Info & Metrics
Related Articles
Cited By...
- No citing articles found.